The global cancer microbiome sequencing market is anticipated to observe impressive growth during the forecast period, 2023-2027. The major factors include growing occurrences of cancer and increasing emphasis on the microbiome’s potential in the field of cancer are fueling the growth of the market.
Rising Prevalence of Cancer supports the Market Growth
Increasing Emphasis by Researchers on the Microbiome’s Potential and Rising Support from Biotechnology Companies.
The rising focus on the microbiome’s potential to diagnose, and prevent various cancers is fueling the growth of the market. Various researchers are studying and researching the microbiome’s potential in the field of cancers. Researchers are being supported by biotech companies to unravel insights pertaining to microbiome’s influence on cancer progression and manifestation. Furthermore, the development of cancer microbiome sequencing services and products have aided the research community to create effective strategies for discovering novel cancer biomarkers allied with the microbiome, which could be used for the development of cancer microbiome sequencing products for clinical use.
Download Free Sample Report
Market Segmentation
In terms of country, the United States is expected to be a lucrative market in the forecast period due rising incidences of cancer and rise in R&D activities in the country.
Market Players
Illumina, Inc., Eurofins Scientific SE, QIAGEN NV, Thermo Fischer Scientific, Inc., Oxford Nanopore Technologies plc., OraSure Technologies, Inc., Pacific Biosciences of California, Inc., Psomagen, Inc, Prescient Medicine Holdings, Inc., and Micronoma Inc.
Attribute | Details |
Base Year | 2021 |
Historic Data | 2017 – 2020 |
Estimated Year | 2022 |
Forecast Period | 2023 – 2027 |
Quantitative Units | Revenue in USD Million, Volume Units and CAGR for 2017-2021 and 2022-2027 |
Report coverage | Revenue forecast, Volume forecast company share, competitive landscape, growth factors, and trends |
Segments covered | · Component · Technology · Application · End User · Company |
Regional scope | North America; Asia Pacific; Europe & CIS; South America; Middle East & Africa |
Country scope | United States; Canada; Mexico; China; India; Japan; South Korea; Germany; France; United Kingdom; Spain; Italy; Brazil; Argentina; Colombia; South Africa; UAE; Saudi Arabia; South Africa; Australia; Turkey; Egypt; |
Key companies profiled | Illumina, Inc., Eurofins Scientific SE, QIAGEN NV, Thermo Fischer Scientific, Inc., Oxford Nanopore Technologies plc., OraSure Technologies, Inc., Pacific Biosciences of California, Inc., Psomagen, Inc, Prescient Medicine Holdings, Inc., and Micronoma Inc. |
Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |